Takayasu Kurata
Université Paris-Sud
2 papers in the Anchorcite directory, published between 2017 and 2018, cited 12,394 times in total.
ORCID profileResearch topics
- Lung Cancer Diagnosis and Treatment · 2 papers
- Lung Cancer Treatments and Mutations · 2 papers
- Cancer Immunotherapy and Biomarkers · 1 paper
- HER2/EGFR in Cancer Research · 1 paper
Frequent co-authors
- Jhanelle E. Gray · 2 papers
- Leena Gandhi · 1 paper
- Delvys Rodríguez‐Abreu · 1 paper
- Shirish M. Gadgeel · 1 paper
- Emilio Esteban · 1 paper
- Enriqueta Felip · 1 paper
- Flávia De Angelis · 1 paper
- Manuel Dómine · 1 paper
Papers
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine · 2018 · 6,754 citations
BACKGROUND: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the…
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine · 2017 · 5,640 citations
BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell…
Metadata from OpenAlex (CC0).